The Satellos team wore red in recognition of #WorldDuchenneAwarenessDay, showing our support for the Duchenne community. This year's theme, #AccessChangesLives, reminds us that together we can help raise awareness and advocate for greater access for everyone living with #Duchenne muscular dystrophy. #WDAD2026 $MSLE $MSCL.TO

$MSLE News: Satellos announced today that the @US_FDA has granted Fast Track designation to SAT-3247 for the treatment of #Duchenne muscular dystrophy. Full details here: ir.satellos.com/news/news-de… $MSCL.TO

Muscle is remarkable. It repairs itself constantly, responding to the demands we place on it every day. In Duchenne muscular dystrophy, that repair process breaks down, and muscles can't keep up with the damage. Satellos is working to change that, with a therapy designed to reset the muscle’s own ability to rebuild. Learn how at satellos.com/science #MuscleRegeneration #Duchenne $MSLE $MSCL.TO

Satellos announced today that its common shares have been approved for listing on the Nasdaq Stock Market LLC and have commenced trading under the ticker “MSLE.” The Company’s common shares continue to trade on TSX under “MSCL.” More here: tinyurl.com/5brx8yuw $MSLE $MSCL #MuscleRegeneration

Satellos is heading to San Francisco for the @jpmorgan Healthcare Conference next week. With BASECAMP, our Phase 2 trial of SAT-3247 in children with #Duchenne, now underway, we look forward to connecting with industry leaders and the investment community to discuss the year ahead. #JPM2026 #MuscleRegeneration $MSCL $MSCLF

The reason behind the research. #MuscleRegeneration #Duchenne $MSCL $MSCLF Learn more at satellos.com

A question that sits at the center of our work. Explore more at satellos.com. #MuscleRegeneration #Duchenne $MSCL $MSCLF

Satellos has reported its Q3 2025 financial results and announced the appointment of Mark Nawacki to its Board of Directors. Read the full release: tinyurl.com/mscl-Q3-25 #MuscleRegeneration #Duchenne $MSCL $MSCLF

#Duchenne News: Today, Satellos announced that the first patient has been dosed in LT-001, an open-label, long-term follow-up study of SAT-3247 in adult males with Duchenne muscular dystrophy. Full details here: tinyurl.com/satellos-fpd #MuscleRegeneration $MSCL $MSCLF

In #Duchenne muscular dystrophy, the body’s natural muscle repair system breaks down. Satellos is studying an investigational approach designed to restore muscle regeneration from within. Watch this short video to see how: tinyurl.com/2xec8zhy #DecodingDuchenne #MuscleRegeneration $MSCL $MSCLF

“In our family, we dare to dream of a different kind of future for Charlie, one where Duchenne exists in a small, dark corner of a big, beautiful life.” -Jennifer, Charlie’s mom On World Duchenne Awareness Day, we celebrate families like Charlie’s — the true heart of care.💙 worldduchenneday.org #WDAD2025 #TheHeartofCare #DuchenneAwarenessDay @DuchenneDay $MSCL $MSCLF

Satellos CEO Frank Gleeson and CMO Dr. Wildon Farwell joined a fireside chat this morning at the Cantor Fitzgerald Global Healthcare Conference. They shared updates on Satellos’ progress, our focus on advancing SAT-3247 for #Duchenne, and the road ahead. Replay now available: tinyurl.com/4zmwrmb5 #MuscleRegeneration #CantorHealthcare $MSCL $MSCLF

We’re honored to support the @JettFoundation annual World Duchenne Awareness Day event tomorrow in Quincy, MA. Two of our Satellos team members will be there, and we’re looking forward to connecting with families, advocates, and everyone who makes this community so special. 💙 #StrongerThanDuchenne #JettFoundationWDAD #wdad2025 $MSCL $MSCLF

In #Duchenne muscular dystrophy, the signal that tells muscle stem cells how to repair and regenerate muscle is missing. This short clip explains what Satellos uncovered — and how we’re studying ways to address that missing signal. Learn more: satellos.com/duchenne #DecodingDuchenne #MuscleRegeneration $MSCL $MSCLF